Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: Results from the Swiss Inflammatory Bowel Disease Cohort Study

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 7, 2013, Pages 790-797

  Sulz, Michael C ^a   Siebert, Uwe ^d,e,f   Arvandi, Marjan ^d   Gothe, Raffaella M ^d   Wurm, Johannes ^d   Von Känel, Roland ^b   Vavricka, Stephan R ^c   Meyenberger, Christa ^a   Sagmeister, Markus ^a  

^a Kantonsspital St Gallen ^*  (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Decision making; inflammatory bowel disease; predictors; resource consumption

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; ANTIBIOTIC AGENT; BUDESONIDE; CERTOLIZUMAB PEGOL; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; STEROID;

ADULT; ARTICLE; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; ENTERITIS; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ULCERATIVE COLITIS;

ADULT; AMBULATORY CARE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; RISK FACTORS; SWITZERLAND; TIME FACTORS;

EID: 84879906468     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32836019b9     Document Type: Article

References (19)

1. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49:777-782.
2. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 2002; 8:244-250.
3. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135:1907-1913.
4. Prenzler A, Bokemeyer B, von der Schulenburg J-M, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ 2011; 12:273-283.
5. Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, et al. European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European Inflammatory Bowel Disease Inception Cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131:719-728.
6. D' Haens G, Hommes D, Baert F. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn' s disease. Gastroenterology 2006; 130: (Suppl 2):A-110.
7. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J-P, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130:650-656.
8. Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, et al. Swiss IBD Cohort Study Group. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009; 38: 922-931.
9. Roberts RO, Bergstrahl EJ, Schmidt L, Jacobsen SJ. Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol 1996; 49:989-995.
10. Ritter PL, Stewart AL, Kaymaz H, Sobel DS, Block DA, Lorig KR. Self-reports of health care utilization compared to provider records. J Clin Epidemiol 2001; 54:136-141.
11. Goosens MEJB, Rutten-van Mölken MPMH, Vlaeyen JWS, van der Linden SMJP. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000; 53:688-695.
12. Naber AH, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med 2003; 61:105-110.
13. Herrmann C, Buss U, Snaith R. Hospital Anxietyand Depression Scale-Deutsche Version (HADS-D). Bern: Hans Huber; 1995.
14. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43:948-954.
15. Nugent Z, Blanchard JF, Bernstein CN. A population-based study of healt-care resource use among infliximab users. Am J Gastroenterol 2010; 105:2009-2016.
16. Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988; 23:1147-1152.
17. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001; 96:2113-2116.
18. Odes S. How expensive is inflammatory bowel disease? World J Gastroenterol 2008; 14:6641-6647.
19. Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econom 2003; 4:143-150.